Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Clinical Tests During Treatment

The Forsteo Summary of Product Characteristics does not specify laboratory tests to monitor; however, available literature offers suggestions on clinical work up during therapy.

Follow up Tests to Teriparatide Therapy

Follow up tests to teriparatide therapy that may be utilized include1

  • total serum calcium

    • If symptoms such as nausea, vomiting, constipation, lower energy, or muscle weakness arise, as these may be signs of high blood calcium

  • LS and TH BMD by DXA after 24 months of therapy.1

References

1. Miller PD, Bilezikian JP, Deal C, et al. Clinical use of teriparatide in the real world: initial insights. Endocr Pract. 2004;10(2):139-148. http://dx.doi.org/10.4158/EP.10.2.139

Glossary

BMD = bone mineral density

DXA = dual-energy x-ray absorptiometry

LS = lumbar spine

TH = total hip

Date of Last Review: January 21, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question